NDAINTRAVENOUSINJECTABLE
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ARGATROBAN IN 0.9% SODIUM CHLORIDE (argatroban) by Teva is site. Approved for heparin-induced thrombocytopenia, thrombosis, coronary artery bypass graft surgery. First approved in 2014.
Drug data last refreshed 23h ago
Mechanism of Action
site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C;…
Indications (3)
Worked on ARGATROBAN IN 0.9% SODIUM CHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.